Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors
08 11월 2021 - 8:00PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that John Maraganore, Ph.D., founding chief executive
officer and director of Alnylam Pharmaceuticals, has joined the
company’s board of directors.
“John is a pioneer and leader in the biopharma community and has
been responsible for building some of the most successful biotech
companies and patient-centric drug development programs of our
time. He brings tremendous experience leading companies from drug
discovery stages through commercialization, and we are thrilled to
welcome him to the Beam board of directors,” said John Evans, chief
executive officer of Beam Therapeutics. “2021 has been a
significant year for Beam, including the recent clearance of our
Investigational New Drug application for BEAM-101, enabling our
transition to a clinical-stage organization. Along with the rest of
the board, I look forward to partnering with John as we continue
building the leading company in the field of precision genetic
medicines.”
“Beam has positioned itself as a true innovator in the field of
gene editing, which has the potential to change both the treatment
approach and the course of disease for patients with a wide range
of severe genetically-driven diseases,” said Dr. Maraganore. “The
company is at an important inflection point as it prepares to
advance the first-ever base editor into clinical development for
people with sickle cell disease. I look forward to contributing to
these efforts and working with the great team at Beam as they
pursue their goal of bringing important new gene editing medicines
to patients.”
Dr. Maraganore has served as the founding CEO and a director of
Alnylam since 2002, where he has built and led the company from
early platform research on RNA interference through global approval
and commercialization of the first three RNAi medicines including
ONPATTRO®, GIVLAARI®, and
OXLUMO®. Prior to Alnylam, Dr. Maraganore served
as an officer and a member of the management team for Millennium
Pharmaceuticals, Inc., most recently as senior vice president,
strategic product development where he was responsible for the
company’s product franchises in oncology, and cardiovascular,
inflammatory, and metabolic diseases. Before Millennium, he served
as director of molecular biology and director of market and
business development at Biogen, Inc. At Biogen, Dr. Maraganore
invented and led the discovery and development of ANGIOMAX®
(bivalirudin) for injection, formerly HIRULOG™ and currently
marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore
was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr.
Maraganore received his M.S. and Ph.D. in biochemistry and
molecular biology at the University of Chicago. He is a member of
the board of Agios Pharmaceuticals and Biotechnology Innovation
Organization (BIO), where he was Chair from 2017-2019.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that enables precise, predictable
and efficient single base changes, at targeted genomic sequences,
without making double-stranded breaks in the DNA. This enables a
wide range of potential therapeutic editing strategies that Beam is
using to advance a diversified portfolio of base editing programs.
Beam is a values-driven organization committed to its people,
cutting-edge science, and a vision of providing life-long cures to
patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned not to place undue
reliance on these forward-looking statements, including, but not
limited to, statements related to: the commencement of clinical
trials for BEAM-101; and the therapeutic applications and potential
of our technology, including our ability to develop life-long,
curative, precision genetic medicines for patients through base
editing. Each forward-looking statement is subject to important
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statement,
including, without limitation, risks and uncertainties related to:
our ability to develop, obtain regulatory approval for, and
commercialize our product candidates, which may take longer or cost
more than planned; our ability to raise additional funding, which
may not be available; our ability to obtain, maintain and enforce
patent and other intellectual property protection for our product
candidates; the potential impact of the COVID-19 pandemic; that
preclinical testing of our product candidates and preliminary or
interim data from preclinical studies and clinical trials may not
be predictive of the results or success of ongoing or later
clinical trials; that enrollment of our clinical trials may take
longer than expected; that our product candidates may experience
manufacturing or supply interruptions or failures; risks related to
competitive products; and the other risks and uncertainties
identified under the headings “Risk Factors Summary” and “Risk
Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2020, our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021, and our Quarterly Report on Form 10-Q
for the quarter ended June 30, 2021, and in any subsequent filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release. Factors
or events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable
law.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024